Compare MLYS & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | USNA |
|---|---|---|
| Founded | 2019 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 397.1M |
| IPO Year | 2023 | 1996 |
| Metric | MLYS | USNA |
|---|---|---|
| Price | $25.93 | $14.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $48.67 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 169.8K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,060,902,000.00 |
| Revenue This Year | N/A | $3.90 |
| Revenue Next Year | N/A | $6.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.30 | $12.57 |
| 52 Week High | $47.65 | $28.52 |
| Indicator | MLYS | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.89 | 46.71 |
| Support Level | $25.56 | $12.57 |
| Resistance Level | $31.36 | $15.75 |
| Average True Range (ATR) | 1.66 | 0.52 |
| MACD | -0.32 | 0.11 |
| Stochastic Oscillator | 10.32 | 33.14 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).